Vuong Trieu

5.1k total citations · 2 hit papers
92 papers, 4.1k citations indexed

About

Vuong Trieu is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Vuong Trieu has authored 92 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 34 papers in Molecular Biology and 33 papers in Cancer Research. Recurrent topics in Vuong Trieu's work include Cancer Treatment and Pharmacology (28 papers), Lipoproteins and Cardiovascular Health (12 papers) and Cancer, Hypoxia, and Metabolism (12 papers). Vuong Trieu is often cited by papers focused on Cancer Treatment and Pharmacology (28 papers), Lipoproteins and Cardiovascular Health (12 papers) and Cancer, Hypoxia, and Metabolism (12 papers). Vuong Trieu collaborates with scholars based in United States, Italy and Russia. Vuong Trieu's co-authors include Neil Desai, Patrick Soon‐Shiong, Fatih M. Uckun, Michael Hawkins, Tapas De, Andrew Yang, Walter J. McConathy, B Damascelli, Daniel D. Von Hoff and Leslie Louie and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Biochemistry.

In The Last Decade

Vuong Trieu

82 papers receiving 4.0k citations

Hit Papers

Increased antitumor activity, intratumor paclitaxel conce... 2006 2026 2012 2019 2006 2011 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
    2006 901 citations Neil Desai, Vuong Trieu et al. profile →
  2. Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
    2011 823 citations Neil Desai, Vuong Trieu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vuong Trieu United States 23 2.0k 1.2k 969 889 607 92 4.1k
Andreas Wicki Switzerland 27 1.5k 0.8× 1.8k 1.4× 1.1k 1.2× 453 0.5× 462 0.8× 81 4.6k
Fumiaki Koizumi Japan 35 1.5k 0.8× 1.9k 1.5× 620 0.6× 887 1.0× 251 0.4× 109 3.9k
Deliang Fu China 28 1.3k 0.7× 994 0.8× 370 0.4× 621 0.7× 471 0.8× 99 2.7k
Chong-xian Pan United States 31 1.6k 0.8× 1.7k 1.4× 329 0.3× 504 0.6× 614 1.0× 104 4.2k
Paul Bhar United States 15 2.1k 1.1× 709 0.6× 1.0k 1.1× 617 0.7× 201 0.3× 34 3.6k
Àngels Fabra Spain 39 1.9k 1.0× 3.1k 2.6× 501 0.5× 1.1k 1.3× 307 0.5× 84 5.3k
Jia Wei China 37 1.6k 0.8× 1.5k 1.2× 328 0.3× 541 0.6× 353 0.6× 177 3.9k
Hua Guo China 38 816 0.4× 2.4k 2.0× 368 0.4× 1.2k 1.3× 571 0.9× 161 4.5k
Hilary Calvert United Kingdom 31 2.6k 1.3× 2.2k 1.8× 394 0.4× 610 0.7× 222 0.4× 79 5.0k
Jihui Hao China 32 1.2k 0.6× 1.4k 1.2× 442 0.5× 792 0.9× 200 0.3× 117 3.1k

Countries citing papers authored by Vuong Trieu

Since Specialization
Citations

This map shows the geographic impact of Vuong Trieu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vuong Trieu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vuong Trieu more than expected).

Fields of papers citing papers by Vuong Trieu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vuong Trieu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vuong Trieu. The network helps show where Vuong Trieu may publish in the future.

Co-authorship network of co-authors of Vuong Trieu

This figure shows the co-authorship network connecting the top 25 collaborators of Vuong Trieu. A scholar is included among the top collaborators of Vuong Trieu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vuong Trieu. Vuong Trieu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Saif, Muhammad Wasif, et al.. (2025). TGFB2 Expression and Methylation Predict Overall Survival in Pancreatic Ductal Adenocarcinoma Patients. International Journal of Molecular Sciences. 26(13). 6357–6357.
2.
Trieu, Vuong, et al.. (2025). Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer. npj Breast Cancer. 11(1). 58–58. 1 indexed citations
3.
Qazi, Sanjive, Wen‐Han Chang, Cynthia Wei‐Sheng Lee, & Vuong Trieu. (2024). Abstract B070: TGFB2 mRNA levels prognostically interact with Interferon-alpha receptor activation of IRF9 and IFI27, and makers for tumor-associated macrophages impacting overall survival in PDAC. Cancer Research. 84(17_Supplement_2). B070–B070. 1 indexed citations
4.
Uckun, Fatih M., Sanjive Qazi, & Vuong Trieu. (2023). High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma. Cancers. 15(6). 1676–1676. 6 indexed citations
5.
6.
Uckun, Fatih M., et al.. (2020). Selectively targeting TGF-β with Trabedersen/OT-101 in treatment of evolving and mild ards inCOVID-19. Clinical Investigation. 10(2). 35–44. 1 indexed citations
7.
8.
9.
D’Cruz, Osmond J., et al.. (2018). Impact of targeting transforming growth factor β-2 with antisense OT-101 on the cytokine and chemokine profile in patients with advanced pancreatic cancer. OncoTargets and Therapy. Volume 11. 2779–2796. 21 indexed citations
10.
11.
Hwang, Lindsay, Kouros Motamed, & Vuong Trieu. (2014). IG-001—A Non-Biologic Micellar Paclitaxel Formulation for the Treatment of Metastatic Breast Cancer. Annals of Oncology. 25. i25–i25. 2 indexed citations
12.
Motamed, Kouros, et al.. (2014). Discordance Between Unbound Paclitaxel Plasma Levels and Efficacy—Lessons From Tocosol-Paclitaxel. Annals of Oncology. 25. i25–i25. 1 indexed citations
13.
Trieu, Vuong, et al.. (2008). Pharmacokinetic and ADME study of nanoparticle albumin-bound 17AAG (nab-17AAG) in mice. Cancer Research. 68. 5747–5747. 2 indexed citations
14.
Trieu, Vuong, Tapas De, & Neil Desai. (2008). Toxicology and safety pharmacology of nanoparticle albumin-bound (nab) rapamycin (ABI-009). Cancer Research. 68. 5732–5732. 1 indexed citations
15.
Desai, Neil, Tapas De, Sherry Ci, Leslie Louie, & Vuong Trieu. (2008). Characterization and in vitro/in vivo dissolution of nab-paclitaxel nanoparticles. Cancer Research. 68. 5624–5624. 7 indexed citations
16.
Trieu, Vuong, et al.. (2007). SPARC overexpression enhances sensitivity to nab-paclitaxel in vivo. Cancer Research. 67. 3480–3480. 4 indexed citations
17.
De, Tapas, Vuong Trieu, Andrew Yang, et al.. (2007). Nanoparticle albumin-bound (nab) rapamycin as an anticancer agent. Cancer Research. 67. 4719–4719. 5 indexed citations
18.
Trieu, Vuong, Sophia Ran, & Neil Desai. (2007). Investigation of chemotherapy-induced tumor angiogenesis: Rationale for combination of nab-paclitaxel with anti-VEGF therapy. Cancer Research. 67. 4636–4636. 1 indexed citations
19.
Trieu, Vuong & Fatih M. Uckun. (2000). Apolipoprotein E and Apolipoprotein D Expression in a Murine Model of Singlet Oxygen-Induced Cerebral Stroke. Biochemical and Biophysical Research Communications. 268(3). 835–841. 9 indexed citations
20.
McConathy, Walter J., et al.. (1994). Triglyceride-rich lipoprotein interactions with Lp(a). Chemistry and Physics of Lipids. 67-68. 105–113. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andreas Wicki Breakdown of academic impact, for papers by Fumiaki Koizumi Breakdown of academic impact, for papers by Deliang Fu Breakdown of academic impact, for papers by Chong-xian Pan Breakdown of academic impact, for papers by Paul Bhar Breakdown of academic impact, for papers by Àngels Fabra Breakdown of academic impact, for papers by Jia Wei Breakdown of academic impact, for papers by Hua Guo Breakdown of academic impact, for papers by Hilary Calvert Breakdown of academic impact, for papers by Jihui Hao
Rankless by CCL
2026